Osteonecrosis of the femoral head: treatment before the collapse. Experience with decompression and biological therapy.

IF 1.4 Q3 ORTHOPEDICS
Yuri Lara-Taranchenko, Iñaki Mimendia, Víctor Barro, María Guzmám, Margalida Hernández, Andrés Aliaga-Martínez, Diego Soza, Diego Collado, Ernesto Guerra Farfán, Alejandro Hernández
{"title":"Osteonecrosis of the femoral head: treatment before the collapse. Experience with decompression and biological therapy.","authors":"Yuri Lara-Taranchenko, Iñaki Mimendia, Víctor Barro, María Guzmám, Margalida Hernández, Andrés Aliaga-Martínez, Diego Soza, Diego Collado, Ernesto Guerra Farfán, Alejandro Hernández","doi":"10.1007/s00590-025-04257-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Osteonecrosis is a disabling condition and one of the most frequent causes of hip arthroplasty in the young population. Early detection and treatment in stages prior to femoral head collapse are essential to prevent progression and conversion to total hip arthroplasty (THA). The present study aims to demonstrate the results obtained in the treatment of patients with initial stages of ONFH, treated with a decompression system that associates biologic therapy (platelet-rich plasma and mesenchymal stem cells) (PERFUSE).</p><p><strong>Methodology: </strong>Retrospective unicentric study, in which all patients with ONFH treated with decompression of the necrotic area and biological therapy between May 2018 and May 2023, was collected. Demographic data of the patients (age and gender), risk factors for AVN, area of necrosis (Kerboul), ARCO classification, collapse rate, and conversion to THA were obtained.</p><p><strong>Results: </strong>Twenty-four patients with ONFH were treated using the PERFUSE system. The mean age was 47.67 years old, and the mean follow-up was 26.1 months. The mean improvement in the modified Harris Hip Score (mHHS) was 10.11 (from 70.79 to 80.56; p = 0.018). Patients who developed femoral head collapse had worse mHHS scores. Six patients (25%) progressed to femoral head collapse, of which 2 (8.33%) were converted to total hip arthroplasty (THA). The probability of collapse-free survival at 12 months was 90.9% (SD 6.2; 95%CI, 79.5%-100%), and at 18 months, it was 85.2% (SD 8.0; 95%CI, 70.9%-100%), and at 24 months, it was 65.7% (SD 11.7; 95%CI, 46.3%-93.2%).</p><p><strong>Conclusion: </strong>Core decompression with bone aspirate marrow and platelet-rich plasma can enhance bone regeneration and delay femoral head collapse, especially when implemented in early-stage ONFH. In this sense, combining both, core decompression with biological support can offer a promising approach for managing early-stage ONFH. Despite encouraging outcomes, further research is needed to optimize treatment protocols and evaluate long-term efficacy.</p>","PeriodicalId":50484,"journal":{"name":"European Journal of Orthopaedic Surgery and Traumatology","volume":"35 1","pages":"145"},"PeriodicalIF":1.4000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Orthopaedic Surgery and Traumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00590-025-04257-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Osteonecrosis is a disabling condition and one of the most frequent causes of hip arthroplasty in the young population. Early detection and treatment in stages prior to femoral head collapse are essential to prevent progression and conversion to total hip arthroplasty (THA). The present study aims to demonstrate the results obtained in the treatment of patients with initial stages of ONFH, treated with a decompression system that associates biologic therapy (platelet-rich plasma and mesenchymal stem cells) (PERFUSE).

Methodology: Retrospective unicentric study, in which all patients with ONFH treated with decompression of the necrotic area and biological therapy between May 2018 and May 2023, was collected. Demographic data of the patients (age and gender), risk factors for AVN, area of necrosis (Kerboul), ARCO classification, collapse rate, and conversion to THA were obtained.

Results: Twenty-four patients with ONFH were treated using the PERFUSE system. The mean age was 47.67 years old, and the mean follow-up was 26.1 months. The mean improvement in the modified Harris Hip Score (mHHS) was 10.11 (from 70.79 to 80.56; p = 0.018). Patients who developed femoral head collapse had worse mHHS scores. Six patients (25%) progressed to femoral head collapse, of which 2 (8.33%) were converted to total hip arthroplasty (THA). The probability of collapse-free survival at 12 months was 90.9% (SD 6.2; 95%CI, 79.5%-100%), and at 18 months, it was 85.2% (SD 8.0; 95%CI, 70.9%-100%), and at 24 months, it was 65.7% (SD 11.7; 95%CI, 46.3%-93.2%).

Conclusion: Core decompression with bone aspirate marrow and platelet-rich plasma can enhance bone regeneration and delay femoral head collapse, especially when implemented in early-stage ONFH. In this sense, combining both, core decompression with biological support can offer a promising approach for managing early-stage ONFH. Despite encouraging outcomes, further research is needed to optimize treatment protocols and evaluate long-term efficacy.

股骨头坏死:塌陷前的治疗。有减压和生物治疗经验。
骨坏死是一种致残性疾病,也是年轻人髋关节置换术的最常见原因之一。股骨头塌陷前的早期发现和治疗对于防止进展和转向全髋关节置换术(THA)至关重要。本研究的目的是证明在初始阶段ONFH患者的治疗中获得的结果,减压系统结合生物治疗(富血小板血浆和间充质干细胞)(PERFUSE)进行治疗。方法:回顾性单中心研究,收集2018年5月至2023年5月期间所有接受坏死区减压和生物治疗的ONFH患者。获得患者的人口学资料(年龄和性别)、AVN的危险因素、坏死面积(Kerboul)、ARCO分类、衰竭率和向THA的转化。结果:24例ONFH患者采用PERFUSE系统治疗。平均年龄47.67岁,平均随访26.1个月。改良Harris髋关节评分(mHHS)的平均改善为10.11(从70.79提高到80.56;p = 0.018)。股骨头塌陷的患者mHHS评分更差。6例(25%)进展为股骨头塌陷,其中2例(8.33%)转为全髋关节置换术(THA)。12个月无塌陷生存的概率为90.9% (SD 6.2;95%CI, 79.5%-100%), 18个月时为85.2% (SD 8.0;95%CI, 70.9%-100%), 24个月时为65.7% (SD 11.7;95%可信区间,46.3% - -93.2%)。结论:骨抽吸骨髓和富血小板血浆对股骨头减压能促进骨再生,延缓股骨头塌陷,尤其适用于早期ONFH。从这个意义上说,结合两者,核心减压和生物支持可以为早期ONFH的治疗提供有希望的方法。尽管结果令人鼓舞,但需要进一步的研究来优化治疗方案和评估长期疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.00
自引率
5.90%
发文量
265
审稿时长
3-8 weeks
期刊介绍: The European Journal of Orthopaedic Surgery and Traumatology (EJOST) aims to publish high quality Orthopedic scientific work. The objective of our journal is to disseminate meaningful, impactful, clinically relevant work from each and every region of the world, that has the potential to change and or inform clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信